Precision BioSciences (DTIL) Competitors $5.67 +0.03 (+0.53%) As of 10:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. PROK, CADL, CRGX, DSGN, ENGN, PLX, OCGN, AMRN, NVCT, and MDWDShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include ProKidney (PROK), Candel Therapeutics (CADL), CARGO Therapeutics (CRGX), Design Therapeutics (DSGN), enGene (ENGN), Protalix BioTherapeutics (PLX), Ocugen (OCGN), Amarin (AMRN), Nuvectis Pharma (NVCT), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. ProKidney Candel Therapeutics CARGO Therapeutics Design Therapeutics enGene Protalix BioTherapeutics Ocugen Amarin Nuvectis Pharma MediWound Precision BioSciences (NASDAQ:DTIL) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends. Do institutionals & insiders have more ownership in DTIL or PROK? 38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 4.0% of Precision BioSciences shares are owned by company insiders. Comparatively, 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, DTIL or PROK? ProKidney has lower revenue, but higher earnings than Precision BioSciences. ProKidney is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.87-$61.32M$1.902.97ProKidney$76K3,410.70-$35.47M-$0.63-1.41 Do analysts rate DTIL or PROK? Precision BioSciences currently has a consensus target price of $47.00, indicating a potential upside of 733.33%. ProKidney has a consensus target price of $5.00, indicating a potential upside of 464.59%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Precision BioSciences is more favorable than ProKidney.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProKidney 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, DTIL or PROK? Precision BioSciences has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Does the media favor DTIL or PROK? In the previous week, ProKidney had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for ProKidney and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.81 beat ProKidney's score of 1.45 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ProKidney 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor DTIL or PROK? Precision BioSciences received 87 more outperform votes than ProKidney when rated by MarketBeat users. Likewise, 68.84% of users gave Precision BioSciences an outperform vote while only 57.14% of users gave ProKidney an outperform vote. CompanyUnderperformOutperformPrecision BioSciencesOutperform Votes9568.84% Underperform Votes4331.16% ProKidneyOutperform Votes857.14% Underperform Votes642.86% Is DTIL or PROK more profitable? Precision BioSciences has a net margin of 11.48% compared to ProKidney's net margin of 0.00%. ProKidney's return on equity of 0.00% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences11.48% -23.69% -6.98% ProKidney N/A N/A -10.24% SummaryPrecision BioSciences beats ProKidney on 11 of the 17 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.50M$3.00B$5.57B$7.83BDividend YieldN/A1.89%5.11%4.21%P/E Ratio94.0230.4222.4418.48Price / Sales0.87498.92394.10103.59Price / CashN/A168.6838.1834.62Price / Book1.253.206.774.25Net Income-$61.32M-$72.35M$3.22B$248.23M7 Day Performance2.55%1.46%1.48%0.89%1 Month Performance25.61%8.79%3.99%3.53%1 Year Performance-46.18%-22.36%16.20%5.08% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.3518 of 5 stars$5.67+0.5%$47.00+728.9%-45.8%$59.82M$68.70M94.52200Positive NewsPROKProKidney2.4919 of 5 stars$0.73-7.3%$5.00+582.2%-57.1%$214.52M$76,000.00-1.333Positive NewsCADLCandel Therapeutics2.2649 of 5 stars$4.51-1.3%$21.00+365.6%-30.4%$213.03M$120,000.00-2.6160Positive NewsCRGXCARGO Therapeutics2.0858 of 5 stars$4.60-0.9%$15.00+226.1%-76.1%$211.84MN/A-1.08116News CoveragePositive NewsHigh Trading VolumeDSGNDesign Therapeutics1.8595 of 5 stars$3.59+2.6%$8.00+122.8%+38.1%$203.78MN/A-4.2240Upcoming EarningsENGNenGene3.402 of 5 stars$3.99-0.3%$24.13+504.6%-74.0%$203.40MN/A-6.8831Analyst ForecastShort Interest ↑PLXProtalix BioTherapeutics2.6897 of 5 stars$2.55-2.3%$15.00+488.2%+169.3%$198.98M$53.40M-19.62200Analyst RevisionNews CoveragePositive NewsOCGNOcugen0.9414 of 5 stars$0.68-0.3%$6.33+835.4%-43.4%$197.72M$4.06M-3.7680AMRNAmarin0.5537 of 5 stars$9.55+4.8%$7.00-26.7%-41.6%$196.10M$228.61M-106.11360Upcoming EarningsAnalyst RevisionGap DownNVCTNuvectis Pharma2.5988 of 5 stars$8.34-5.9%$15.67+87.8%+63.8%$195.09MN/A-7.198Upcoming EarningsAnalyst ForecastNews CoverageMDWDMediWound1.4404 of 5 stars$17.65+3.2%$31.33+77.5%-4.9%$190.76M$20.22M-6.0980 Related Companies and Tools Related Companies ProKidney Alternatives Candel Therapeutics Alternatives CARGO Therapeutics Alternatives Design Therapeutics Alternatives enGene Alternatives Protalix BioTherapeutics Alternatives Ocugen Alternatives Amarin Alternatives Nuvectis Pharma Alternatives MediWound Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DTIL Stock Free DTIL Stock Alerts